Hemolysis Detection Devices Global Market Report 2026

The hemolysis detection devices market size has grown strongly in recent years. It will grow from $0.92 billion in 2025 to $0.99 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing prevalence of hemolytic disorders, rising blood transfusion procedures, growing clinical laboratory testing volumes, adoption of spectrophotometry in diagnostics, increasing regulatory focus on sample quality standards.

The hemolysis detection devices market size is expected to see strong growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for automated laboratory workflows, increasing investment in advanced diagnostic infrastructure, rising adoption of portable point of care devices, expansion of blood bank networks in emerging markets, increasing emphasis on early detection of transfusion related complications. Major trends in the forecast period include increasing adoption of automated hemolysis detection systems, rising demand for high throughput laboratory analyzers, growing integration of spectrophotometric detection technologies, expansion of point of care hemolysis testing, rising focus on blood sample quality control protocols.

The rising clinical trials activity is expected to stimulate the growth of the hemolysis detection devices market in the coming years. Clinical trials activity involves conducting research studies on humans to evaluate the safety and effectiveness of drugs or treatments, with headspace gas analysis ensuring product quality and stability throughout these trials. The expansion of clinical trial activity is fueled by the growing demand for new and effective therapies, driven by the increasing prevalence of chronic and lifestyle diseases, which necessitate more clinical studies to safely assess innovative treatments. Hemolysis detection devices support clinical trials by rapidly detecting the breakdown of red blood cells in blood samples, ensuring sample integrity and accurate laboratory results, which are essential for precise evaluation of drug safety and efficacy. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK trade association, the number of industry clinical trials initiated in the UK reached 426 in 2023, up from 411 in 2022. Therefore, the rising clinical trials activity is driving the growth of the hemolysis detection devices market.

Key companies operating in the hemolysis detection devices market are focusing on developing innovative products such as point-of-care blood gas analyzers with hemolysis detection to enable rapid, accurate, and bedside detection of hemolysis, improving clinical decision-making and patient care. A point-of-care blood gas analyzer with hemolysis detection is a portable diagnostic system that assesses essential blood parameters at the bedside while detecting sample hemolysis that supports fast and reliable clinical decisions by enhancing test accuracy and minimizing errors resulting from red blood cell breakdown. For example, in July 2024, Werfen S.A., a Spain-based diagnostics company, introduced the GEM Premier 7000 with intelligent quality management 3 (iQM3), designed to address key challenges in point-of-care blood gas testing. It combines patented acoustofluidic technology and photometric determination to detect hemolysis within 45 seconds, ensuring accurate potassium and other blood gas measurements. The system features real-time, automated quality checks for hemolysis, micro-clots, bubbles, and lipemia, along with a comprehensive test menu including pH, electrolytes, and CO-oximetry, making it ideal for enhancing patient safety, clinical decision-making, and workflow efficiency in critical care settings.

In March 2025, Advanced Instruments LLC, a US-based manufacturing company, acquired Nova Biomedical Corp. for $2.2 billion. This acquisition enables Advanced Instruments to expand its range of clinical and life science testing solutions, improving capabilities in blood gas, electrolyte, and chemistry analysis for hospitals, laboratories, and research facilities. Nova Biomedical Corp. is a US-based medical device company that manufactures critical care blood gas analyzers, which assess hemoglobin (Hb) and hematocrit (Hct) to identify hemolysis-related issues in whole blood samples.

Major companies operating in the hemolysis detection devices market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson Company, Mindray Bio Medical Electronics Co. Ltd., Sysmex Corporation, Bio Rad Laboratories Inc., Werfen S.A., HORIBA Medical SAS, Greiner Bio One International GmbH, Randox Laboratories Ltd., Agappe Diagnostics Ltd., Guangzhou Wondfo Biotech Co. Ltd., Radiometer Medical ApS, EKF Diagnostics Holdings plc, Hemcheck Sweden AB, Alta DiagnoTech Co. Ltd., Ortho Clinical Diagnostics Inc.

North America was the largest region in the hemolysis detection devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemolysis detection devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemolysis detection devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hemolysis detection devices market consists of sales of hemolysis QC analyzers, serum indices controls, and photometric hemolysis detection readers and test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemolysis detection devices are specialized diagnostic instruments used to identify and quantify the breakdown of red blood cells in blood samples. They detect free hemoglobin released into plasma or serum using spectrophotometric, optical, or biochemical methods. Hemolysis detection devices are primarily employed to maintain sample integrity in clinical laboratories, reduce the risk of inaccurate test results, and support early detection of hemolytic disorders or transfusion-related complications.

The primary product types of hemolysis detection devices include benchtop hemolysis detection devices, portable hemolysis detection devices, and automated hemolysis detection systems. Benchtop devices are laboratory-based solutions designed to provide accurate detection and quantification of hemolysis in blood samples. They use technologies such as spectrophotometry, colorimetry, visual inspection, and others. Applications include blood banks, hospitals, diagnostic laboratories, research institutes, and others, serving hospitals and clinics, blood centers, research and academic institutes, and other end users.

Tariffs on imported diagnostic components, optical sensors, and laboratory analyzers are impacting the hemolysis detection devices market by increasing equipment and production costs, particularly affecting automated hemolysis detection systems and spectrophotometry-based devices. Regions such as North America and Europe that rely on imported laboratory instrumentation components are most affected, along with emerging markets dependent on international suppliers. Hospitals, blood centers, and diagnostic laboratories face higher procurement costs. However, tariffs are also encouraging domestic manufacturing of diagnostic equipment, strengthening local supply chains, and promoting innovation in cost-efficient portable hemolysis detection solutions.

The hemolysis detection devices market research report is one of a series of new reports that provides hemolysis detection devices market statistics, including hemolysis detection devices industry global market size, regional shares, competitors with a hemolysis detection devices market share, detailed hemolysis detection devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemolysis detection devices industry. This hemolysis detection devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.